 |
|
|
| |
VAC-3S, a safe Immunotherapeutic HIV Vaccine decreased total HIV DNA and increased CD4/CD8 ratio: Phase I Final Results.
|
| |
| |
"A trend was found between change of CD4/CD8 ratio at W24 and anti-3S titers at W12 (r=0.29, p=0.11). Globally, a dose-dependent decrease in CD8% has been found (p<0.001, ANOVA test)....At W24, we observed a decrease on CD8%(p=0.027, Wilcoxon paired test) and a significant increase in CD4% (p=0.031, Wilcoxon paired test) in the responder group.....CD4/CD8 ratio, CD8% decreases and CD4% decrease are also observed in 20 μg arm (p=0.03; p=0.03 and p=0.13 respectively; one-tailed Wilcoxon test). Increases in CD4/CD8 ratio and CD4% as well as decrease in CD8% were expected effects. A negative correlation was found between change from baseline of CD4+CD95+% and anti-3S titers at W24 (r=-0,59, p=0.002, Pearson test) suggesting protective effects of anti-3S antibodies of CD4+T cells against by stander apoptosis, in agreement with the mechanism of figure1. Further analysis are ongoing."
---------------
Reported by Jules Levin
Toward an HIV Cure Symposium, July 18-19, 2015, Vancouver
IAS Vancouver 2015
R. Ho Tsong Fang1, O. Launay2, C. Rouzioux5, B. Autran3, J. Capeau4, A. Melard5, M. Marcu1, R. Calin6, H. Bodilis2, J. Crouzet1, V. Vieillard7, P. Debre7, S. Gharakhanian8, C. Katlama9
1InnaVirVax, Evry, France, 2AP-HP Cochin, Universite Paris Descartes & Inserm CIC 1417, Paris, France, 3AP-HP Pitie Salpetriere, Universite Pierre et Marie Curie, InsermU1135, CIMI, Paris, France, 4AP-HP Tenon, CDR St Antoine, Universite Pierre et Marie Curie, INSERM UMR S-938, Paris, France, 5AP-HP Necker, EA 7327 Universite Paris Descartes, Paris, France, 6AP-HP Pitie-Salpetriere Inserm U943, Paris, France, 7AP-HP Pitie Salpetriere, Universite Pierre et Marie Curie, InsermU1135, CIMI, Paris, France, 8InnaVirVax -Cambridge Innovation Center, Cambridge MA, United States, 9Inserm U943, AP-HP Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
|
| |
|
|
|
|
|
